Center specificity in the limited sampling model (LSM): Can the LSM developed from healthy subjects be extended to disease states?

International Journal of Clinical Pharmacology and Therapeutics

Volumn 41, Issue 11, 2003, Pages 517-523

  Mahmood, I ^a  

^a Office of Blood Research and Review   (United States)

Author keywords

Center specificity; Limited sampling model; Renal and hepatic impairment

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; TELMISARTAN; THIAZIDE DIURETIC AGENT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEASUREMENT; PREDICTION; SIMULATION; STATISTICAL MODEL;

EID: 0242606427     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP41517     Document Type: Article

References (21)

1. David O, Johnston A 2000 Limited sampling strategies. Clin Pharmacokinet 39: 311-312
2. Denaro CP, Jacob P, Benowitz NL 1998 Evaluation of pharmacokinetic methods used to estimate caffeine clearance and comparison with a Bayesian forecasting method. Ther Drug Monit 20: 78-87
3. Drusano GL, Forrest A, Snyder MJ, Reed MD, Blumer JL 1988 An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther 44: 232-238
4. Dumont RJ, Ensom M 2000 Reply to limited sampling strategies. Clin Pharmacokinet 39: 312-313
5. Garraffo R, Iliadis A, Cano JP, Dellamonica P, Lapalus P 1989 Application of Bayesian estimation for the prediction of an appropriate dosage regimen of amikacin. J Pharm Sci 78: 753-757
6. Gaulier JM, Boulieu R, Fischer C, Mauguiere F 1997 Predictions of carbamazepine concentrations using a Bayesian program (PKS system, Abbott): a retrospective evaluation in an outpatient population. J Pharm Pharmacol 49: 734-736
7. Ludden M 1988 Population pharmacokinetics. J Clin Pharmacol 28: 1059-1063
8. max). Biopharm Drug Dispos 18: 117-126
9. max of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product. Br J Clin Pharmacol 45: 241-246
10. Mahmood I, Mahayni H 1999 A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies. Int J Clin Pharmacol 37: 275-281
11. Mahmood I 2000 A limited sampling model for the estimation of pharmacokinetic parameters in children. Ther Drug Monit 22: 532-536
12. max: a computer simulation analysis. Int J Clin Pharmacol 37: 439-445
13. Niemeyer C, Hasenfuß G, Wais U, Knauf H, Schafer-Korting M, Mutschler E 1983 Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 24: 661-665
14. Ratain MJ, Staubus AE, Schilsky RL, Malspeis L 1988 Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 48: 4127-4130
15. Ratain MJ, Vogelzang NJ 1987 Limited sampling models for vinblastine pharmacokinetics. Cancer Treat Rep 71: 935-939
16. Schumacher GE 1985 Choosing optimal sampling times for therapeutic drug monitoring. Clin Pharmacol 4: 84-92
17. Sorensen BT, Stromgren A, Jackobson P, Jackobson A 1993 A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31: 324-327
18. Stangier J, Su C-A, Schondorfer G, Roth W 2000 Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 40: 1355-1364
19. max) and area under the curve (AUC). Ther Drug Monit 19: 79-82
20. Warmerdam LJC, Huinink WW, Maes RA, Beijnen JH 1994 Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120: 427-433
21. Williams PJ, Browne JL, Patel RA 1989 Bayesian forecasting of serum lithium concentrations. Comparison with traditional methods. Clin Pharmacokinet 17: 45-52